1. Spain Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Faes Farma, S.A.

Faes Farma, S.A.

FAE.MC
Faes Farma, S.A.ES flagMadrid Stock Exchange
4.59
EUR
+0.03
- -
1.43BMarket Cap
Faes Farma, S.A.
FAE.MC
(Madrid Stock Exchange)

Recent

price

4.59

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.92
0.87
0.78
0.75
0.75
0.78
0.88
1.02
1.17
1.26
1.31
1.32
1.44
1.46
1.59
1.96
1.4
Revenue per Share
0.09
0.06
0.09
0.09
0.1
0.12
0.14
0.15
0.19
0.23
0.25
0.27
0.29
0.3
0.36
0.26
0.28
Basic EPS, GAAP
0.02
0.05
0.09
0.11
0.11
0.12
0.14
0.09
0.14
0.16
0.18
0.07
0.09
- -
0.24
0.18
- -
Free Cash Flow per Basic Share
0.08
0.04
0.03
- -
- -
0.02
0.02
0.02
0.03
0.04
0.04
0.05
0.06
0.05
0.16
0.18
- -
Dividend per Share
0.28
0.25
0.25
0.26
0.26
0.28
0.3
0.32
0.36
0.42
0.46
0.52
0.58
0.64
0.77
0.73
0.49
Book Value per Share
0.23
0.25
0.34
0.38
0.51
0.62
0.75
0.58
0.7
0.86
1.06
1.17
1.39
1.54
1.74
0.92
1.46
Tangible Book Value per Share
219
219
226
242
254
261
261
268
276
284
291
303
306
310
311
311
318
Basic Weighted Avg Shares
203
190
176
180
192
205
229
275
324
357
380
399
439
451
494
610
444
Sales/Revenue/Turnover
11.13
8.82
13.25
16.14
18.96
20.37
21.1
18.1
19.29
22.23
24.35
24.55
23.3
23
22.3
14.92
23.12
Operating Margin (%)
9
9
8
8
6
6
6
8
10
13
15
17
19
19
20
29
20
Depreciation Expense
20
14
20
23
25
30
37
41
52
64
73
82
89
92
111
80
90
Net Income, GAAP
- -
- -
- -
6.58
22.65
22.61
20.57
16.2
16.09
13.68
13.56
11.32
11.81
10.85
- -
6.73
11.82
Effective Tax Rate (%)
9.88
7.45
11.08
12.53
13.21
14.83
16
15.07
15.91
17.9
19.08
20.67
20.4
20.37
22.56
13.04
20.19
Profit Margin (%)
6
9
30
34
59
82
116
113
114
151
205
214
219
203
230
298
217
Working Capital
32
31
34
21
5
- -
- -
43
1
3
2
2
4
4
3
378
5
LT Debt
166
168
185
198
229
254
285
320
360
414
473
537
602
663
727
746
646
Total Equity
- -
- -
- -
11.09
11.64
12.99
13.95
12.56
13.35
16.26
17.44
16.63
15.11
13.92
- -
8.76
14.47
Return on Invested Capital (%)
- -
- -
- -
21.84
28.75
40.87
47.73
38.3
35.54
44.51
51.02
51.11
46.37
42.48
- -
18.56
57.03
Return on Capital (%)
28.87
24.47
35.49
38.34
39.57
43.66
48.62
50.4
55.3
58.49
57.75
56.91
53.38
48.89
50.84
34.11
59.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
28
- -
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
- -
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
318
- -
314
Market Capitalization
1,116
1,001
1,010

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
313
- -
299
Cash, Cash Equivalents & STI
84
- -
47
Accounts Receivable, Net
102
- -
121
Inventories
114
- -
132
Total Current Liabilities
94
- -
82
Payables & Accruals
- -
- -
- -
ST Debt
28
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.41%
9.6%
2.61%
Free Cash Flow
-640.16%
-1,295.91%
-27.72%
Net Income, GAAP
11.33%
3.51%
-28.49%
Sales/Revenue/Turnover
11.73%
10.16%
23.66%
Total Cash Common Dividend
37.46%
55.48%
15.49%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
130
106
- -
- -
451
2024
139
135
232
- -
494
2025
- -
314
- -
- -
610

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.09
- -
- -
- -
0.3
2024
0.1
- -
0.17
- -
0.36
2025
- -
0.09
- -
- -
0.26

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.05
2024
- -
- -
- -
- -
0.16
2025
- -
- -
- -
- -
0.18
Similar Companies
Biofrontera Inc. (BFRIW)
Ipsen S.A. (IPSEY)
Boiron S.A. (BOIRF)
Alpha Teknova, Inc. (TKNO)
Jinling Pharmaceutical Company Limited (000919.SZ)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
Business
Faes Farma, S.A. (FAE.MC) researches, develops, manufactures and markets pharmaceutical products, healthcare specialties, animal nutrition and health solutions, and pharmaceutical raw materials worldwide. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments, offering prescription and generic drugs including the proprietary molecules bilastine for allergies, calcifediol for vitamin D treatments, and mesalazine for gastroenterology; over-the-counter medicines, food supplements and personal care treatments targeting allergies, venous insufficiency, irritable bowel syndrome, bone health, pain relief and immunology; animal nutrition products such as specialized feeds for swine and other species through the FARM Faes division and subsidiaries including Ingaso Farm, Tecnovit and Capselos; and active pharmaceutical ingredients. Faes Farma conducts significant R&D investment, exports to more than 130 countries and maintains direct operations in Europe including Spain, Portugal and Italy, Latin America encompassing Mexico, Colombia, Chile, Peru, Ecuador and Guatemala, as well as Africa and the Middle East; it employs around 1,775 people with headquarters, production facilities and R&D center in Leioa, Spain, additional offices in Madrid and Barcelona, and a new 60,000 square meter plant in Derio completed in 2024 to triple production capacity to 100 million units annually by 2027. Founded in 1933, the company listed on the Madrid Stock Exchange in the 1940s and pursues international expansion through strategic acquisitions including Laboratorios Edol, a Portuguese ophthalmology firm, for 75 million euros in March 2025 to double sales in Portugal; SIFI, an Italian ophthalmic specialist, for 270 million euros in September 2025, its largest deal and elevating ophthalmology to nearly 20 percent of revenues; and earlier purchases of Initial Technical Foods in 2017 alongside diversification into animal nutrition via Ingaso in 2007; it also advances new offerings such as high-dose metocarbamol tablets for pain relief, mesalazina granules clinical trials, iFEROL vitamin D analogues in 2025, alongside investments in a 150 million euro Huesca facility for animal feed aiming to double that segment's revenues by 2027-2028.